DCM
SPRB

DAFNA Capital Management’s Spruce Biosciences SPRB Stock Holding History

DAFNA Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,313
Closed -$1.61M – 82
2023
Q4 		$1.61M Sell
7,313
-289
-4% -$33.4K 0.39% 50
2023
Q3 		$1.29M Buy
7,602
+3,442
+83% +$580K 0.4% 48
2023
Q2 		$671K Hold
4,160
– – 0.18% 60
2023
Q1 		$690K Buy
+4,160
New +$773K 0.21% 56

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DAFNA Capital Management's SPRB Position: Q1 2024 in Review

DAFNA Capital Management sold out of Spruce Biosciences (SPRB) in Q1 2024, closing a stake of 7,313 shares — an estimated $1.61M sold.

DAFNA Capital Management first reported a position in SPRB in Q1 2023 and held it in 4 quarters. The position peaked at $1.61M in Q4 2023. 49 funds tracked by Wall St. Rank hold SPRB as of Q1 2024.

  • DAFNA Capital Management reported no remaining Spruce Biosciences position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 7,313 Spruce Biosciences shares in Q1 2024, an estimated $1.61M.
  • DAFNA Capital Management first reported a position in Spruce Biosciences in Q1 2023 and held it in 4 quarters.
  • DAFNA Capital Management's Spruce Biosciences position peaked at $1.61M in Q4 2023.
  • 49 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.